Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2019

04.01.2019 | Original Article

Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer

verfasst von: Daniel Walacides, M.D., Astrid Meier, M.D., Anne Caroline Knöchelmann, M.D., Daniele Meinecke, M.D., Thorsten Derlin, M.D., Frank M. Bengel, M.D., Tobias L. Ross, PhD, Hans-Jürgen Wester, PhD, Katja Derlin, M.D., Markus A. Kuczyk, M.D., Christoph A. J. von Klot, M.D., Hans Christiansen, M.D., Christoph Henkenberens, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the differences in the target volume (TV) delineation of metachronous lymph node metastases between 68 Ga-PSMA ligand PET/CT and conventional imaging in a comparative retrospective contouring study.

Patients and methods

Twenty-five patients with biochemical prostate cancer recurrence after primary prostatectomy underwent 68 Ga-PSMA ligand PET/CT in addition to conventional imaging techniques such as CT and/or MR imaging for restaging. All patients were diagnosed with at least one lymph node metastasis. TVs were manually delineated in two different ways: (a) based on conventional imaging (CT/MRI) and (b) based on conventional imaging (CT/MRI) plus 68 Ga-PSMA ligand PET/CT. The size of TVs, overlap rates, and subjective assessment of the difficulty of TV delineation reported by the radiation oncologist (easy/moderate/difficult) were compared.

Results

With the additional information from PSMA ligand PET, 47 lymph node metastases were identified and included in the gross tumor volume (GTV). The median clinical target volume (CTV) of non-PET-based TV delineation was statistically larger than the CTV based on PET imaging (134.8 ml [range 6.9–565.2] versus 44.9 ml [range 4.9–481.3; p = 0.001]). The CTV based on CT/MRI enclosed only 81.3% (39/48) of PET-positive lymph nodes. The CT/MRI-based CTV did not enclose all PET-positive lymph nodes in 24% (6/25) of patients. In 12% (3/25) of patients, all PET-positive lymph nodes were outside of the CT/MRI-based CTV. The median overlap rates (TVPET/TVCT/MRI × 100) were 45.7% (range 0–96.9) for the GTV and 71.7% (range 9.8–98.2) for the CTV. The assessment of difficulty of contouring revealed that contouring with the additional imaging information of the PET was categorized as easy/moderate in 92% (23/25) and as difficult in 8% (2/25) of the cases, whereas contouring based on CT/MRI without PET was categorized as difficult in 56% (14/25) and as easy/moderate in 44% of the cases (11/25; p = 0.003).

Conclusion

68 Ga-PSMA ligand PET/CT is superior to conventional cross-sectional imaging for the delineation of lymph node metastases from prostate cancer. PET-based TV delineation allows for smaller target volumes and should be considered the standard for irradiation of metachronous lymph node metastases in recurrent prostate cancer. Conventional imaging is not sufficiently sensitive for radio-oncological treatment concepts in oligometastatic prostate cancer.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics. Ca Cancer J Clin 65:87–108CrossRefPubMed Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics. Ca Cancer J Clin 65:87–108CrossRefPubMed
2.
Zurück zum Zitat Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523CrossRefPubMed Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523CrossRefPubMed
3.
Zurück zum Zitat Pund CR, Partin AW, Epstein JI et al (1997) Prostate-specific antigen after anatomical retropubic prostatectomy. Pattern of recurrence and cancer control. Urol Clin North Am 24:395–406CrossRef Pund CR, Partin AW, Epstein JI et al (1997) Prostate-specific antigen after anatomical retropubic prostatectomy. Pattern of recurrence and cancer control. Urol Clin North Am 24:395–406CrossRef
4.
Zurück zum Zitat Ost P, Decaestecker K, Lambert B et al (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74:297–305CrossRefPubMed Ost P, Decaestecker K, Lambert B et al (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74:297–305CrossRefPubMed
5.
Zurück zum Zitat Ost P, Reynders D, Decaestecker K (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence. J Clin Oncol 36:446–453CrossRefPubMed Ost P, Reynders D, Decaestecker K (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence. J Clin Oncol 36:446–453CrossRefPubMed
6.
Zurück zum Zitat Oderda M, Joniau S, Palazzetti A et al (2018) Is 11C-choline positron emission tomography/computed tomography accurate to detect nodal relapses of prostate cancer after biochemical recurrence? A Multicentric study based on pathologic conformation from salvage Lymphadenectomy. Eur Urol Focus 4:288–293CrossRefPubMed Oderda M, Joniau S, Palazzetti A et al (2018) Is 11C-choline positron emission tomography/computed tomography accurate to detect nodal relapses of prostate cancer after biochemical recurrence? A Multicentric study based on pathologic conformation from salvage Lymphadenectomy. Eur Urol Focus 4:288–293CrossRefPubMed
7.
Zurück zum Zitat Afshar-Oromieh A, Holland-Letz T, Giesel FL et al (2017) Diagnostic performance of 68GaPSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 44:1258–1268CrossRefPubMedPubMedCentral Afshar-Oromieh A, Holland-Letz T, Giesel FL et al (2017) Diagnostic performance of 68GaPSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 44:1258–1268CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Schmuck S, von Klot CA, Henkenberens C et al (2017) Initial experience with volumetric 68 ga-PSMA I&T PET/CT for assessment for whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58:1962–1968CrossRefPubMed Schmuck S, von Klot CA, Henkenberens C et al (2017) Initial experience with volumetric 68 ga-PSMA I&T PET/CT for assessment for whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58:1962–1968CrossRefPubMed
11.
Zurück zum Zitat Schmuck S, Nordlohne S, von Klot CA et al (2017) Comparison of standard and delayed imaging to improve the detection rate of [68 Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 44:960–968CrossRefPubMed Schmuck S, Nordlohne S, von Klot CA et al (2017) Comparison of standard and delayed imaging to improve the detection rate of [68 Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 44:960–968CrossRefPubMed
13.
Zurück zum Zitat Henkenberens C, von Klot CA, Ross TL et al (2016) 68 Ga-PSMA ligand PET7CT based radiotherapy in locally recurrenct and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol 192:431–439CrossRefPubMed Henkenberens C, von Klot CA, Ross TL et al (2016) 68 Ga-PSMA ligand PET7CT based radiotherapy in locally recurrenct and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol 192:431–439CrossRefPubMed
14.
Zurück zum Zitat Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209CrossRefPubMed Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209CrossRefPubMed
15.
Zurück zum Zitat Giesel FL, Fiedler H, Stefanova M et al (2015) PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68 Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(12):1794–1800CrossRefPubMedPubMedCentral Giesel FL, Fiedler H, Stefanova M et al (2015) PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68 Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(12):1794–1800CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rinnab L, Mottaghy FM, Simon J et al (2008) [11 C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197CrossRefPubMed Rinnab L, Mottaghy FM, Simon J et al (2008) [11 C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197CrossRefPubMed
17.
Zurück zum Zitat Perera M, Papa N, Christidis D et al (2016) Sensitivity, specifity and predictors of positive 68 ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed Perera M, Papa N, Christidis D et al (2016) Sensitivity, specifity and predictors of positive 68 ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed
18.
Zurück zum Zitat Derlin T, Weiberg D, von Klot C et al (2016) 68 Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345–4353CrossRefPubMed Derlin T, Weiberg D, von Klot C et al (2016) 68 Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345–4353CrossRefPubMed
19.
Zurück zum Zitat Weineisen M, Schottelius J, Simecek J et al (2015) 68 Ga- and 177LU-labeled PSA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176CrossRefPubMed Weineisen M, Schottelius J, Simecek J et al (2015) 68 Ga- and 177LU-labeled PSA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176CrossRefPubMed
20.
Zurück zum Zitat Martin R, Jüttler S, Müller M, Wester HJ (2014) Cationic eluate pretreatment for automated synthesis of [68 Ga]CPCR4.2. Nucl Med Biol 41:84–89CrossRefPubMed Martin R, Jüttler S, Müller M, Wester HJ (2014) Cationic eluate pretreatment for automated synthesis of [68 Ga]CPCR4.2. Nucl Med Biol 41:84–89CrossRefPubMed
21.
Zurück zum Zitat Hövels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 64:387–395CrossRef Hövels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 64:387–395CrossRef
22.
Zurück zum Zitat Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid (6)(8)ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674CrossRefPubMed Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid (6)(8)ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674CrossRefPubMed
23.
Zurück zum Zitat Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041CrossRefPubMedPubMedCentral Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Rauscher I, Maurer T, Beer AJ et al (2016) Value of 68 ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with Histopathology after salvage Lymphadenectomy. J Nucl Med 57:1713–1719CrossRefPubMed Rauscher I, Maurer T, Beer AJ et al (2016) Value of 68 ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with Histopathology after salvage Lymphadenectomy. J Nucl Med 57:1713–1719CrossRefPubMed
25.
Zurück zum Zitat van Leeuwen PJ, Emmett L, Ho B et al (2017) Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed van Leeuwen PJ, Emmett L, Ho B et al (2017) Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed
27.
Zurück zum Zitat Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419CrossRefPubMed Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419CrossRefPubMed
28.
Zurück zum Zitat Rischke HC, Schultze-Seemann W, Wieser G et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 4:310–320CrossRef Rischke HC, Schultze-Seemann W, Wieser G et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 4:310–320CrossRef
29.
Zurück zum Zitat Picchio M, Berardi G, Fodor A et al (2014) 11C-choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer. Eur J Nucl Med Mol Imaging 41:1270–1279CrossRefPubMed Picchio M, Berardi G, Fodor A et al (2014) 11C-choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer. Eur J Nucl Med Mol Imaging 41:1270–1279CrossRefPubMed
30.
Zurück zum Zitat Schick U, Jorcano S, Nouet P et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52:1622–1628CrossRefPubMed Schick U, Jorcano S, Nouet P et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52:1622–1628CrossRefPubMed
32.
Zurück zum Zitat Zamboglou C, Drendel V, Jilg CA et al (2017) Comparison of 68 Ga-HBED-CC PSMA-PET/CT and multiparametric mRI for grosstumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 7:228–237CrossRefPubMedPubMedCentral Zamboglou C, Drendel V, Jilg CA et al (2017) Comparison of 68 Ga-HBED-CC PSMA-PET/CT and multiparametric mRI for grosstumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 7:228–237CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Sanli Y, Kuyumcu S, Sanli O et al (2017) Relationships between serum PSA levels, Gleason scores and results of 68 Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med 31:709–717CrossRefPubMed Sanli Y, Kuyumcu S, Sanli O et al (2017) Relationships between serum PSA levels, Gleason scores and results of 68 Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med 31:709–717CrossRefPubMed
34.
Zurück zum Zitat Berliner C, Tienken M, Frenzel T et al (2017) Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68 Ga]PSMA I&T and comparison with published data of [68 Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging 44:670–677CrossRefPubMed Berliner C, Tienken M, Frenzel T et al (2017) Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68 Ga]PSMA I&T and comparison with published data of [68 Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging 44:670–677CrossRefPubMed
Metadaten
Titel
Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer
verfasst von
Daniel Walacides, M.D.
Astrid Meier, M.D.
Anne Caroline Knöchelmann, M.D.
Daniele Meinecke, M.D.
Thorsten Derlin, M.D.
Frank M. Bengel, M.D.
Tobias L. Ross, PhD
Hans-Jürgen Wester, PhD
Katja Derlin, M.D.
Markus A. Kuczyk, M.D.
Christoph A. J. von Klot, M.D.
Hans Christiansen, M.D.
Christoph Henkenberens, M.D.
Publikationsdatum
04.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-018-1417-9

Weitere Artikel der Ausgabe 5/2019

Strahlentherapie und Onkologie 5/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.